Premium
RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS
Author(s) -
Fedorova L.,
Lepik K.,
Mikhailova N.,
Kondakova E.,
Zalyalov Y.,
Baykov V.,
Babenko E.,
Borzenkova E.,
Tsvetkova L.,
Stelmakh L.,
Afanasyev B.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.176_2631
Subject(s) - medicine , nivolumab , discontinuation , lymphoma , refractory (planetary science) , population , combination therapy , oncology , surgery , cancer , immunotherapy , physics , environmental health , astrobiology